Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

The challenge persists, but, with a renewed focus from regulatory bodies and trial sponsors alike on improving enrolment ...

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Welcome back to Changing Faces for the month of July. We’re trying something new this month. Rather than consigning the many Board appointments we hear about each month to a long bulleted list ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category for ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 million to ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...